Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 20Terminated 8Recruiting 3Active not recruiting 3Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 32NIH 6INDUSTRY 3NETWORK 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Hematologic Neoplasms 2Sarcoma, Myeloid 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Daunorubicin × Clear all
NCT07007312 2026-06-03

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology, Inc.

Phase 3 Recruiting
1,300 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06578247 2026-04-30

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡